Page last updated: 2024-08-21

alpha-aminopyridine and Pulmonary Embolism

alpha-aminopyridine has been researched along with Pulmonary Embolism in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Anthony, S; Bajaj, A; Bhundia, V; Branson, A; Brookes, C; Darlison, L; Dawson, AG; Fennell, DA; Gaba, A; Greystoke, A; Hutka, M; King, A; Mohammed, S; Morgan, B; Nusrat, N; Poile, C; Richards, C; Scotland, M; Thomas, A; Wells-Jordan, P	1

Trials

1 trial(s) available for alpha-aminopyridine and Pulmonary Embolism

Article	Year
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. The Lancet. Oncology, 2022, Volume: 23, Issue:3 Topics: Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Diarrhea; Hemoptysis; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Pulmonary Embolism; Respiratory Tract Infections; Sepsis; Thrombocytopenia; Vomiting	2022

Article

Year

Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.

The Lancet. Oncology, 2022, Volume: 23, Issue:3

Topics: Alanine Transaminase; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Diarrhea; Hemoptysis; Humans; Mesothelioma; Mesothelioma, Malignant; Pleural Neoplasms; Pulmonary Embolism; Respiratory Tract Infections; Sepsis; Thrombocytopenia; Vomiting

2022